International
The Morning Science

What science found today

‹
 

Research

Can Adjuvant Pembrolizumab Improve Outcomes in Triple-Negative Breast Cancer?

MedPage Today ·

Can Adjuvant Pembrolizumab Improve Outcomes in Triple-Negative Breast Cancer?

The Brief

  • MedPage Today published a video preview by Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care, on the phase III SWOG-S1418/NRG Oncology BR006 trial.
  • The trial studies adjuvant pembrolizumab (Keytruda) in triple-negative breast cancer.
  • The source is a short preview snippet and does not report the trial's results.

Why it matters

Triple-negative breast cancer is an aggressive subtype with limited targeted options, so results from a phase III trial of adjuvant pembrolizumab could bear on post-surgery treatment decisions.

Who’s affected

  • oncologists and breast cancer clinicians
  • patients with triple-negative breast cancer and their families

(MedPage Today) -- In this exclusive MedPage Today video, Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care in California, previews findings from the phase III SWOG-S1418/NRG Oncology BR006 trial of adjuvant pembrolizumab (Keytruda) in...

How do you feel about this?

0 Comments

    Can Adjuvant Pembrolizumab Improve Outcomes in Triple-Negative Breast Cancer? – The Morning Science